| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 11 | 2021 | 127 | 3.120 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 145 | 2.480 |
Why?
|
| Leptin | 9 | 2021 | 118 | 2.480 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2020 | 23 | 2.430 |
Why?
|
| Prostatic Neoplasms | 7 | 2023 | 935 | 2.230 |
Why?
|
| Adenocarcinoma | 9 | 2010 | 251 | 2.200 |
Why?
|
| Fibronectins | 4 | 2020 | 66 | 2.030 |
Why?
|
| Liver Neoplasms | 9 | 2023 | 190 | 1.980 |
Why?
|
| Cell Line, Tumor | 25 | 2021 | 2231 | 1.540 |
Why?
|
| Gallic Acid | 2 | 2022 | 15 | 1.530 |
Why?
|
| Apoptosis | 16 | 2020 | 1398 | 1.470 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 2015 | 23 | 1.450 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2021 | 269 | 1.450 |
Why?
|
| Barrett Esophagus | 5 | 2009 | 31 | 1.300 |
Why?
|
| Cell Proliferation | 13 | 2020 | 1198 | 1.280 |
Why?
|
| Cyclooxygenase 2 | 9 | 2019 | 104 | 1.210 |
Why?
|
| Gastrins | 4 | 2009 | 9 | 1.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 441 | 1.100 |
Why?
|
| Neoplasms | 5 | 2023 | 1103 | 1.070 |
Why?
|
| Hepatitis B | 3 | 2023 | 38 | 1.070 |
Why?
|
| Exons | 4 | 2020 | 88 | 1.060 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 111 | 1.000 |
Why?
|
| Humans | 49 | 2023 | 37093 | 0.960 |
Why?
|
| Adiponectin | 4 | 2013 | 55 | 0.960 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2013 | 15 | 0.950 |
Why?
|
| Signal Transduction | 9 | 2020 | 1908 | 0.890 |
Why?
|
| Janus Kinase 2 | 6 | 2013 | 32 | 0.890 |
Why?
|
| GTP Phosphohydrolases | 2 | 2021 | 30 | 0.870 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 807 | 0.860 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2021 | 10 | 0.820 |
Why?
|
| New York City | 5 | 2023 | 220 | 0.770 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 222 | 0.770 |
Why?
|
| Glioblastoma | 1 | 2021 | 55 | 0.760 |
Why?
|
| Plasmacytoma | 1 | 2020 | 11 | 0.750 |
Why?
|
| Up-Regulation | 5 | 2019 | 513 | 0.740 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 26 | 0.740 |
Why?
|
| Oncogene Protein v-akt | 2 | 2012 | 20 | 0.740 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 111 | 0.730 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 48 | 0.720 |
Why?
|
| Receptors, Oxytocin | 1 | 2019 | 9 | 0.710 |
Why?
|
| Gene Dosage | 1 | 2019 | 75 | 0.700 |
Why?
|
| Oxytocin | 1 | 2019 | 25 | 0.690 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 219 | 0.690 |
Why?
|
| Cell Division | 4 | 2008 | 307 | 0.680 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 213 | 0.640 |
Why?
|
| Enzyme Activation | 9 | 2021 | 444 | 0.640 |
Why?
|
| Cell Separation | 2 | 2015 | 93 | 0.630 |
Why?
|
| Male | 16 | 2023 | 20025 | 0.610 |
Why?
|
| Colonic Neoplasms | 4 | 2011 | 186 | 0.610 |
Why?
|
| Vaccination | 1 | 2019 | 288 | 0.610 |
Why?
|
| Emigrants and Immigrants | 1 | 2019 | 137 | 0.610 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 661 | 0.600 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2006 | 77 | 0.600 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 409 | 0.600 |
Why?
|
| Diet | 2 | 2022 | 801 | 0.570 |
Why?
|
| Transcription Factors | 1 | 2021 | 681 | 0.560 |
Why?
|
| Cell Movement | 6 | 2020 | 571 | 0.560 |
Why?
|
| Epithelial Cells | 1 | 2019 | 384 | 0.550 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 126 | 0.530 |
Why?
|
| Mice | 10 | 2020 | 5913 | 0.500 |
Why?
|
| Translocation, Genetic | 3 | 2020 | 42 | 0.490 |
Why?
|
| Animals | 16 | 2020 | 15081 | 0.490 |
Why?
|
| MicroRNAs | 2 | 2017 | 426 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 8 | 0.450 |
Why?
|
| Sulfonamides | 7 | 2011 | 80 | 0.450 |
Why?
|
| NF-kappa B | 4 | 2008 | 339 | 0.430 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 1371 | 0.430 |
Why?
|
| STAT3 Transcription Factor | 3 | 2013 | 90 | 0.400 |
Why?
|
| Prognosis | 4 | 2020 | 739 | 0.400 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2019 | 623 | 0.380 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 219 | 0.380 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 10 | 0.370 |
Why?
|
| Epoprostenol | 1 | 2010 | 25 | 0.370 |
Why?
|
| Pyrazoles | 5 | 2010 | 85 | 0.360 |
Why?
|
| Cadherins | 3 | 2019 | 90 | 0.360 |
Why?
|
| Prostate | 2 | 2023 | 154 | 0.350 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2007 | 41 | 0.330 |
Why?
|
| Obesity | 2 | 2008 | 1067 | 0.330 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2011 | 93 | 0.320 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 122 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 172 | 0.320 |
Why?
|
| Dinoprostone | 4 | 2012 | 63 | 0.320 |
Why?
|
| Receptors, Adiponectin | 1 | 2008 | 5 | 0.310 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 22 | 0.310 |
Why?
|
| RNA, Messenger | 4 | 2019 | 1207 | 0.300 |
Why?
|
| Cell Line | 3 | 2019 | 1354 | 0.300 |
Why?
|
| Acids | 1 | 2007 | 18 | 0.300 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 5 | 0.300 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 77 | 0.300 |
Why?
|
| Phosphorylation | 5 | 2011 | 928 | 0.300 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 98 | 0.290 |
Why?
|
| Endothelial Cells | 1 | 2010 | 308 | 0.290 |
Why?
|
| Female | 8 | 2023 | 20969 | 0.280 |
Why?
|
| Disease Progression | 3 | 2019 | 601 | 0.280 |
Why?
|
| Phosphotransferases | 1 | 2006 | 35 | 0.280 |
Why?
|
| Colitis | 1 | 2007 | 65 | 0.280 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 42 | 0.270 |
Why?
|
| Aged | 4 | 2022 | 6741 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 239 | 0.260 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1067 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 187 | 0.260 |
Why?
|
| Adipose Tissue | 1 | 2006 | 177 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 251 | 0.250 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 173 | 0.240 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 515 | 0.230 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2009 | 30 | 0.220 |
Why?
|
| Hepatitis B, Chronic | 1 | 2023 | 10 | 0.220 |
Why?
|
| Gene Expression | 2 | 2019 | 674 | 0.220 |
Why?
|
| Cell Differentiation | 2 | 2020 | 587 | 0.220 |
Why?
|
| HT29 Cells | 3 | 2007 | 45 | 0.210 |
Why?
|
| Cause of Death | 1 | 2023 | 156 | 0.210 |
Why?
|
| Cytokines | 1 | 2006 | 602 | 0.210 |
Why?
|
| Databases, Genetic | 2 | 2019 | 93 | 0.210 |
Why?
|
| tRNA Methyltransferases | 1 | 2021 | 1 | 0.210 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 4 | 0.210 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 118 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 19 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 502 | 0.200 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 20 | 0.200 |
Why?
|
| Vimentin | 2 | 2012 | 37 | 0.200 |
Why?
|
| Methyltransferases | 1 | 2021 | 58 | 0.190 |
Why?
|
| Risk Factors | 2 | 2019 | 3562 | 0.190 |
Why?
|
| Vegetables | 1 | 2022 | 147 | 0.190 |
Why?
|
| Fruit | 1 | 2022 | 173 | 0.190 |
Why?
|
| Middle Aged | 3 | 2019 | 10129 | 0.180 |
Why?
|
| Africa | 1 | 2019 | 76 | 0.180 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 68 | 0.180 |
Why?
|
| Endostatins | 1 | 2019 | 5 | 0.170 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 113 | 0.170 |
Why?
|
| RNA | 1 | 2021 | 241 | 0.170 |
Why?
|
| Mollusk Venoms | 1 | 2019 | 22 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2019 | 15 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 21 | 0.170 |
Why?
|
| Survival Rate | 1 | 2019 | 311 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2023 | 400 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2019 | 126 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 40 | 0.160 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 441 | 0.160 |
Why?
|
| Hospitalization | 1 | 2021 | 388 | 0.160 |
Why?
|
| Liver | 2 | 2019 | 479 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2026 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 583 | 0.160 |
Why?
|
| Mutation | 2 | 2019 | 1095 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2022 | 454 | 0.150 |
Why?
|
| Cell Survival | 3 | 2013 | 864 | 0.150 |
Why?
|
| RNA Interference | 2 | 2009 | 243 | 0.150 |
Why?
|
| Tyrphostins | 2 | 2008 | 15 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 661 | 0.150 |
Why?
|
| Receptors, Leptin | 2 | 2007 | 13 | 0.150 |
Why?
|
| Cell Membrane | 1 | 2019 | 381 | 0.140 |
Why?
|
| Peptides | 1 | 2019 | 320 | 0.140 |
Why?
|
| Logistic Models | 1 | 2019 | 923 | 0.140 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 307 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2008 | 172 | 0.140 |
Why?
|
| Age Factors | 1 | 2019 | 1033 | 0.140 |
Why?
|
| Interleukin-8 | 2 | 2007 | 60 | 0.140 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 144 | 0.140 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2006 | 95 | 0.130 |
Why?
|
| Mass Screening | 1 | 2019 | 462 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 132 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 560 | 0.130 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2013 | 7 | 0.120 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 33 | 0.110 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2379 | 0.110 |
Why?
|
| Mesoderm | 1 | 2013 | 70 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 18 | 0.110 |
Why?
|
| Niacinamide | 1 | 2012 | 15 | 0.110 |
Why?
|
| Models, Biological | 2 | 2013 | 677 | 0.110 |
Why?
|
| Cell Transplantation | 1 | 2012 | 3 | 0.100 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 7 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 48 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 935 | 0.100 |
Why?
|
| Albumins | 1 | 2012 | 26 | 0.100 |
Why?
|
| Collagen Type I | 1 | 2012 | 30 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 43 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2721 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 32 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 767 | 0.100 |
Why?
|
| Models, Animal | 1 | 2011 | 134 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 494 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 93 | 0.100 |
Why?
|
| Base Sequence | 1 | 2013 | 997 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 515 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 864 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 152 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2011 | 212 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 6 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1568 | 0.090 |
Why?
|
| Imidazoles | 2 | 2011 | 126 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2013 | 325 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 448 | 0.090 |
Why?
|
| Young Adult | 1 | 2019 | 4268 | 0.090 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2009 | 4 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 859 | 0.080 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2008 | 9 | 0.080 |
Why?
|
| Adolescent | 1 | 2019 | 5363 | 0.080 |
Why?
|
| RNA Stability | 1 | 2008 | 26 | 0.080 |
Why?
|
| Pravastatin | 1 | 2008 | 6 | 0.080 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2008 | 8 | 0.080 |
Why?
|
| Lovastatin | 1 | 2008 | 10 | 0.080 |
Why?
|
| Mevalonic Acid | 1 | 2008 | 9 | 0.080 |
Why?
|
| Okadaic Acid | 1 | 2008 | 15 | 0.080 |
Why?
|
| Nitrobenzenes | 1 | 2008 | 19 | 0.080 |
Why?
|
| Simvastatin | 1 | 2008 | 29 | 0.080 |
Why?
|
| Sesquiterpenes | 1 | 2008 | 32 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2008 | 176 | 0.080 |
Why?
|
| Quinazolines | 1 | 2008 | 33 | 0.080 |
Why?
|
| Multienzyme Complexes | 1 | 2008 | 69 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2008 | 100 | 0.080 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2008 | 58 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2008 | 130 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2008 | 207 | 0.070 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2007 | 20 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 29 | 0.070 |
Why?
|
| Dextran Sulfate | 1 | 2007 | 15 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2008 | 106 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2008 | 118 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2008 | 103 | 0.070 |
Why?
|
| Adult | 2 | 2019 | 11712 | 0.070 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 3 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 550 | 0.070 |
Why?
|
| Maleimides | 1 | 2006 | 13 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 19 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Anthracenes | 1 | 2006 | 13 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Isoquinolines | 1 | 2006 | 45 | 0.070 |
Why?
|
| Nitriles | 1 | 2006 | 69 | 0.070 |
Why?
|
| Sulfones | 1 | 2006 | 44 | 0.070 |
Why?
|
| Morpholines | 1 | 2006 | 69 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 433 | 0.070 |
Why?
|
| Tyrosine | 1 | 2006 | 118 | 0.070 |
Why?
|
| Chromones | 1 | 2006 | 54 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 177 | 0.070 |
Why?
|
| Flavonoids | 1 | 2006 | 87 | 0.070 |
Why?
|
| Pyridines | 1 | 2006 | 116 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 135 | 0.060 |
Why?
|
| Minority Groups | 2 | 2023 | 596 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 259 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 85 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 161 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 313 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1039 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 136 | 0.060 |
Why?
|
| Indoles | 1 | 2006 | 158 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2006 | 184 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2019 | 435 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 13 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2007 | 1518 | 0.050 |
Why?
|
| Mentors | 1 | 2023 | 127 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2005 | 517 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3483 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2020 | 26 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 51 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 69 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 111 | 0.040 |
Why?
|
| New Jersey | 1 | 2017 | 15 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2017 | 42 | 0.040 |
Why?
|
| Vietnam | 1 | 2017 | 50 | 0.040 |
Why?
|
| Hawaii | 1 | 2023 | 1929 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 213 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 229 | 0.040 |
Why?
|
| Genomics | 1 | 2016 | 223 | 0.030 |
Why?
|
| Antibodies, Immobilized | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 75 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 59 | 0.030 |
Why?
|
| raf Kinases | 1 | 2012 | 7 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2012 | 53 | 0.030 |
Why?
|
| ras Proteins | 1 | 2012 | 51 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 150 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 214 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2011 | 23 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2011 | 75 | 0.020 |
Why?
|
| Naphthoquinones | 1 | 2011 | 36 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 151 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 43 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 487 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 82 | 0.020 |
Why?
|
| United States | 1 | 2016 | 4223 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 803 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 173 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 893 | 0.020 |
Why?
|